| Literature DB >> 24997151 |
Haiqing Ma1, Saradhi Mallampati2, Yue Lu3, Baohua Sun2, Enze Wang2, Xiaohong Leng4, Yun Gong5, Haifa Shen6, C Cameron Yin7, Dan Jones8, Hesham M Amin7, M James You7, Patrick Zweidler-McKay9, Yupo Ma10, Hagop M Kantarjian11, Ralph B Arlinghaus4, Armand Glassman12, Xiaoping Sun13.
Abstract
The transcription factor Sox4 plays an indispensable role in the development of early progenitor B cells from hematopoietic stem cells. However, its role in B-cell acute lymphoblastic leukemia, a malignant counterpart of normal progenitor B cells, is not fully understood. Here we show that SOX4 is highly expressed in human acute lymphoblastic leukemia cells. To systematically study the function of Sox4 in acute lymphoblastic leukemia, we established a genetically defined mouse leukemia model by transforming progenitor B cells carrying a floxed Sox4 allele and inducing deletion of the allele by the self-excising Cre recombinase. This model allowed us to work with two groups of leukemic cells that had either one copy or both copies of Sox4 deleted. We found that depletion of Sox4 in transformed cells in vitro reduced cell growth in vitro and the progression of leukemia in vivo. Moreover, depletion of Sox4 in leukemic cells in vivo prolonged the survival of the mice, suggesting that it could be a potential target in acute lymphoblastic leukemia therapy. Our microarray and bioChIP studies revealed that Tcf7l1 was the key gene directly regulated by Sox4. Knockdown of Tcf7l1 reduced cell proliferation, just as did knockout of Sox4, and ectopic expression of Tcf7l1 could reverse the effect of Sox4 knockout on cell proliferation. These data suggest that Sox4 and Tcf7l1 form a functional axis that promotes the progression of BCR-ABL-positive acute lymphoblastic leukemia. Copyright© Ferrata Storti Foundation.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24997151 PMCID: PMC4181255 DOI: 10.3324/haematol.2014.104695
Source DB: PubMed Journal: Haematologica ISSN: 0390-6078 Impact factor: 9.941